Clinical trials: PD-1 Inhibitors
Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
1. Background and Rationale:: Galectin-3 (Gal-3) is a β-galactoside-binding protein involved in various biological processes, including cell proliferation, apoptosis, adhesion, and immune regulation.
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Transitional Cell Carcinoma
- Trial name
- NCT07485114
- Testing
- Serum Gal-3 level, blood count and chemistry included liver function
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Daniel Keizman
Non Small Cell Lung Cancer
Lindera Obtusiloba for Non-small Cell Lung Cancer
This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1…
- Trial name
- NCT04348149
- Testing
- Lindera obtusiloba extract
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Jun-Yong Choi
Liver Cancer
Probiotics Enhance the Treatment of PD-1 Inhibitors in Patients With Liver Cancer
Human microbes have been called "the second genome of humanity".On May 13,2016,the White House launched the National Microbiome Initiative (NMI), with an estimated investment of us $521 million, to elevate microbiome research to…
- Trial name
- NCT05032014
- Testing
- M9
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Advanced Refractory Solid Tumors
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors
- Trial name
- NCT04892498
- Testing
- Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF
- Where
- 16 sites in China
- Volunteers
- 66 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Small Cell Lung Cancer Limited Stage
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
The study is a prospective, multi-center, open-label, randomized, and controlled phase II clinical trial.
- Trial name
- NCT04189094
- Testing
- Sintilimab, Etoposide, Cisplatin
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
This was a phase II clinical study. Patients with histologically confirmed, resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) without distant metastasis were enrolled.
- Trial name
- NCT07780877
- Testing
- Standard adjuvant radiotherapy based on pathologic findings, De-escalated radiotherapy with a reduced dose, De-escalated radiotherapy with omission of ENI
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Fudan University
Nsclc
Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer
This study is a single-center, randomized controlled, phase II clinical trial, aiming at giving a comparison of Sintilimab and Pembrolizumab in stage IIIB-IV NSCLC patients at first-line treatment setting.
- Trial name
- NCT04252365
- Testing
- Sintilimab, Pembrolizumab
- Volunteers
- 20 people
- Sponsor
- Guangdong Association of Clinical Trials
Pancreatic Cancer Resectable
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
The goal of this clinical trial is to learn if surufatinib (VEGFR-TKI) plus toripalimab (PD-1 inhibitor) and mFOLFIRINOX (chemotherapy) works as neoadjuvant therapy for patients with high-risk or borderline resectable pancreatic…
- Trial name
- NCT07469956
- Testing
- Surufatinib, Toripalimab, mFOLFIRINOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Rectal Adenocarcinoma
SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally advanced rectal cancer (LARC).
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy, Rectal Cancer Patients
- Trial name
- NCT07198165
- Testing
- PD-1 inhibitor based immunotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma
This is a prospective, open-label, non-randomized, two-cohort, single-arm Phase 2 study in adults with unresectable or recurrent/metastatic head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma.
- Trial name
- NCT07683507
- Testing
- Becotatug Vedotin Combined with PD-1 Inhibitor
- Volunteers
- 60 people
- Sponsor
- Feng Liu
PD-1 Antibodies, Exercise
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
Checkpoint inhibitors like the PD-1 antibodies Pembrolizumab and Nivolumab represent standard of care for patients with metastasized melanoma.
- Conditions
- PD-1 Antibodies, Exercise, Melanoma
- Trial name
- Sportivumab (NCT03171064)
- Testing
- Resistance and Endurance Exercise
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- University Hospital Heidelberg
Non-small Cell Lung Cancer
The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC
Over 65% of all lung cancer patients experience significant weight loss fuelled by a catabolic state that is represented by enhanced protein breakdown.
- Trial name
- NutriCim (NCT05902260)
- Testing
- Nutritional intervention, Immunotherapy
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- Joachim Aerts, MD PhD
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Non-Small Cell Lung Cancer
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with…
- Trial name
- LuCa-MERIT-1 (NCT05142189)
- Testing
- BNT116, Cemiplimab, Docetaxel
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 320 people
- Sponsor
- BioNTech SE
Hepatocellular Carcinoma
A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma.
- Trial name
- HZ-T-PD1-APA (NCT03793725)
- Testing
- SHR1210, Apatinib
- Volunteers
- 30 people
- Sponsor
- Yanqiao Zhang
Acute Myeloid Leukemia
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
- Trial name
- NCT05772273
- Testing
- Azacitidine, Donor lymphocyte infusion, Camrelizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
This study is a superiority multi-center, open-label, phase III randomized controlled trial. It will further verify the clinical value of xidili single-antibody combined with chemotherapy (albumin paclitaxel and carboplatin) in…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
- Trial name
- NCT07827872
- Testing
- Sintilimab, Nab-Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- caohaotian
Solid Tumors
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
The goal of this clinical trial is to learn if the combination of lenvatinib and a PD-1 inhibitor (a type of immunotherapy) works to treat advanced solid tumors that have a specific genetic change called "11q13 amplification".
- Trial name
- NCT07417501
- Testing
- Lenvatinib plus PD-1 Inhibitor
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Tongji Hospital
Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
SBRT Combined with CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, Microsatellite Stable (MSS), Unresectable Metastatic Colorectal Cancer (mCRC): a Single-center, Single-arm, Open-label Clinical Trail
- Conditions
- Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer
- Trial name
- NCT06835179
- Testing
- SBRT, PD-1 Inhibitors, CapeOX + bevacizumab
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Carcinoma, Radiotherapy
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
The goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.
- Conditions
- Esophageal Carcinoma, Radiotherapy, Immunotherapy
- Trial name
- NCT06964568
- Testing
- PD-1 inhibitor, Unlimited radiotherapy, TP regimen
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Fudan University